Antigens derived from melanocyte differentiation proteins: Self-tolerance, autoimmunity, and use for cancer immunotherapy

Immunological Reviews

Volumn 188, Issue , 2002, Pages 136-146

  Engelhard, Victor H ^a   Bullock, Timothy N J ^a   Colella, Teresa A ^a   Sheasley, Stacey L ^a   Mullins, David W ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD8 ANTIGEN; DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 14; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELANOCYTE DIFFERENTIATION PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; DIFFERENTIATION ANTIGEN; MONOPHENOL MONOOXYGENASE; PEPTIDE FRAGMENT; SUBUNIT VACCINE; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNITY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; MELANOCYTE; NONHUMAN; PRIORITY JOURNAL; VITILIGO; ADOPTIVE IMMUNOTHERAPY; ALBINISM; ANIMAL; ANTIGEN PRESENTATION; AUTOIMMUNE DISEASE; CHEMISTRY; COMPARATIVE STUDY; EXPERIMENTAL MELANOMA; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MELANOMA; MOUSE; NEOPLASM; REVIEW; SPECIES DIFFERENCE; T LYMPHOCYTE SUBPOPULATION; TRANSGENIC MOUSE; TRANSPLANTATION;

ALBINISM; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, DIFFERENTIATION; ANTIGENS, NEOPLASM; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; MELANOCYTES; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, TRANSGENIC; MONOPHENOL MONOOXYGENASE; NEOPLASM PROTEINS; NEOPLASMS; PEPTIDE FRAGMENTS; SELF TOLERANCE; SPECIES SPECIFICITY; T-LYMPHOCYTE SUBSETS; VACCINES, SUBUNIT; VITILIGO;

EID: 0036812718     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2002.18812.x     Document Type: Article

References (85)

1. Rosenberg SA, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988;319:1676-1680.
2. Brichard V, et al. The tyrosinase gene codes for an antigen recognized by autologous cytotoxic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993;178:489-495.
3. Wolfel T, Schneider J, Meyer zum Buschenfelde KH, Rammensee HG, Rotzschke O, Falk K. Isolation of naturally processed peptides recognized by cytolytic T lymphocytes (CTL) on human melanoma cells in association with HLA-A2.1. Int J Cancer 1994;57:413-418.
4. Robbins PF, el-Gamil M, Kawakami Y, Stevens E, Yannelli JR, Rosenberg SA. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res 1994;54:3124-3126.
5. Skipper JCA, et al. An HLA-A2 restricted tyrosinase antigen on melanoma cells results from post-translational modification and suggests a novel processing pathway for membrane proteins. J Exp Med 1996;183:527-534.
6. Brichard VG, et al. A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. Eur J Immunol 1996;26:224-230.
7. Kittlesen DJ, et al. Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: Implications for tumor vaccine development. J Immunol 1998;160:2099-2106.
8. Cox AL, et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994;264:716-719.
9. Bakker AB, et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 1994;179:1005-1009.
10. Kawakami Y, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995;154:3961-3968.
11. Skipper JCA, et al. Shared epitopes for HLA-A3 restricted melanoma reactive human CTL include a naturally processed epitope from Pmel-17/gp100. J Immunol 1996;157:5027-5033.
12. Kawashima I, Tsai V, Southwood S, Takesako K, Celis E, Sette A. Identification of gp100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells. Int J Cancer 1998;78:518-524.
13. Skipper JCA, et al. Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally-processed forms of CTL epitopes from MART-1 and gp100. Int J Cancer 1999;82:669-677.
14. Kawakami Y, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347-352.
15. + cytotoxic T lymphocytes. J Exp Med 1995;181:363-368.
16. Wang RF, Robbins PF, Kawakami Y, Kang XQ, Rosenberg SA. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med 1995;181:799-804.
17. Wang RF, Appella E, Kawakami Y, Kang X, Rosenberg SA. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 1996;184:2207-2216.
18. Parkhurst MR, Fitzgerald EB, Southwood S, Sette A, Rosenberg SA, Kawakami Y. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res 1998;58:4895-4901.
19. Noppen C, et al. Naturally processed and concealed HLA-A2.1-restricted epitopes from tumor-associated antigen tyrosinase-related protein-2. Int J Cancer 2000;87:241-246.
20. Bloom MB, et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 1997;185:453-459.
21. Pass HA, Schwarz SL, Wunderlich JR, Rosenberg SA. Immunization of patients with melanoma peptide vaccines: Immunologic assessment using the ELISPOT assay. Cancer J Sci Am 1998;4:316-323.
22. Nestle FO, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-332.
23. Rosenberg SA, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-327.
24. Jager E, et al. Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides. Int J Cancer 2000;86:538-547.
25. Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB. Vitiligo in patients with metastatic melanoma: A good prognostic sign. J Am Acad Dermatol 1983;9:689-696.
26. Bystryn J-C, Rigel D, Friedman RJ, Kopf A. Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol 1987;123:1053-1055.
27. Rosenberg SA, White DE. Vitiligo in patients with melanoma - Normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Biol 1996;19:81-84.
28. Parkhurst MR, et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 1996;157:2539-2548.
29. Valmori D, et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 1998;160:1750-1758.
30. Engelhard VH. Direct identification of tumor-associated peptide antigens. Springer Semin Immunopath 1996;18:171-183.
31. + cytotoxic T cell with apparent high affinity. J Immunol 1997;158:5797-5804.
32. Hirschowitz EA, et al. Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma. Gene Ther 1998;5:975-983.
33. Schreurs MW, et al. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Cancer Res 2000;60:6995-7001.
34. Zhai Y, et al. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. J Immunol 1996;156:700-710.
35. Ribas A, et al. Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells. J Immunother 2000;23:59-66.
36. Overwijk WW, et al. gp100/pmel 17 is a murine tumor rejection antigen, induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 1998;188:277-286.
37. Newberg MH, Smith DH, Haertel SB, Vining DR, Lacy E, Engelhard VH. Importance of MHC class I α2 and α3 domains in the recognition of self and non-self MHC molecules. J Immunol 1996;156:2473-2480.
38. Engelhard VH, Lacy E, Ridge JP. Influenza A specific, HLA-A2.1 restricted cytotoxic T lymphocytes from HLA-A2.1 transgenic mice recognize fragments of the M1 protein. J Immunol 1991;146:1226-1232.
39. Vitiello A, Marchesini D, Furze J, Sherman LA, Chestnut RW. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J Exp Med 1991;173:1007-1015.
40. Man S, et al. Definition of a human T cell epitope from influenza A non- structural protein 1 using HLA-A2.1 transgenic mice. Int Immunol 1995;7:597-605.
41. Shirai M, et al. CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1. J Immunol 1995;154:2733-2742.
42. Wentworth PA, et al. Identification of A2-restricted hepatitis C virus-specific cytotoxic T lymphocyte epitopes from conserved regions of the viral genome. Int Immunol 1996;8:651-659.
43. Wentworth PA, et al. Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice. Eur J Immunol 1996;26:97-101.
44. Colella TA, et al. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: Implications for tumor immunotherapy. J Exp Med 2000;191:1221-1232.
45. Engelhard VH, Bullock TN, Colella TA, Mullins DW. Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use. Cancer J Sci Am 2000;6:S272-S280.
46. Mullins DW, Bullock TN, Colella TA, Robila VV, Engelhard VH. Immune responses to the HLA-A*0201-restricted epitopes of tyrosinase and glycoprotein 100 enable control of melanoma outgrowth in HLA-A*0201-transgenic mice. J Immunol 2001;167:4853-4860.
47. Rinchik EM, Stoye JP, Frankel WN, Coffin J, Kwon BS, Russell LB. Molecular analysis of viable spontaneous and radiation-induced albino (c)-locus mutations in the mouse. Mut Res 1993;286:199-207.
48. Tief K, Hahne M, Schmidt A, Beermann F. Tyrosinase, the key enzyme in melanin synthesis, is expressed in murine brain. Eur J Biochem 1996;241:12-16.
49. Battyani Z, Xerri L, Hassoun J, Bonerandi JJ, Grob JJ. Tyrosinase gene expression in human tissues. Pigment Cell Res 1993;6:400-405.
50. Bullock TNJ, Colella TA, Engelhard VH. The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice. J Immunol 2000;164:2354-2361.
51. + T cells for melanoma immunotherapy in human MHC class I-transgenic mice. J Immunol 2001;167:5824-5831.
52. Zhai YF, et al. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens Mart1 and gp100. J Immunother Emphasis Tumor Biol 1997;20:15-25.
53. Kaplan JM, et al. Induction of anti-tumor immunity using dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J Immunol 1999;163:699-707.
54. Bronte V, et al. Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res 2000;60:253-258.
55. van Elsas A, et al. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: Comparison of prophylaxis and therapy. J Exp Med 2001;194:481-489.
56. Bellone M, et al. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. J Immunol 2000;165:2651-2656.
57. Steitz J, Bruck J, Steinbrink K, Enk A, Knop J, Tuting T. Genetic immunization of mice with human tyrosinase-related protein 2: Implications for the immunotherapy of melanoma. Int J Cancer 2000;86:89-94.
58. Metharom P, Ellem KA, Schmidt C, Wei MQ. Lentiviral vector-mediated tyrosinase-related protein 2 gene transfer to dendritic cells for the therapy of melanoma. Hum Gene Ther 2001;12:2203-2213.
59. Li J, Holmes LM, Franek KJ, Wagner TE, Wei Y. Murine tyrosinase expressed by a T7 vector in bone marrow-derived dendritic progenitors effectively prevents and eradicates melanoma tumors in mice. Cancer Gene Ther 2000;7:1448-1455.
60. Nonacs R, Humborg C, Tam JP, Steinman RM. Mechanisms of mouse spleen dendritic cell function in the generation of influenza-specific, cytolytic T lymphocytes. J Exp Med 1992;176:519-529.
61. + cytotoxic T lymphocytes by dendritic cells. J Exp Med 1987;166:182-194.
62. Porgador A, Gilboa E. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 1995;182:255-260.
63. Mayordomo JI, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995;1:1297-1302.
64. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LJ. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 1996;183:283-287.
65. Gabrilovich DI, Nadaf S, Corak J, Berzofsky JA, Carbone DP. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Cell Immunol 1996;170:111-119.
66. Zitvogel L, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation and T helper cell 1-associated cytokines. J Exp Med 1996;183:87-97.
67. Nair SK, Snyder D, Rouse BT, Gilboa E. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 1997;70:706-715.
68. Mukherji B, et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA 1995;92:8078-8082.
69. Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 1996;56:2479-2483.
70. Panelli MC, et al. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J Immunother 2000;23:487-498.
71. Jonuleit H, et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 2001;93:243-251.
72. Banchereau J, et al. Immune and clinical responses in patients with metastatic melanoma to CD34 (+) progenitor-derived dendritic cell vaccine. Cancer Res 2001;61:6451-6458.
73. Alexander-Miller MA, Leggatt GR, Sarin A, Berzofsky JA. Role of antigen, CD8 and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J Exp Med 1996;184:485-492.
74. Grohmann U, et al. A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state. J Immunol 1997;158:3593-3602.
75. Toes RE, et al. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J Immunol 1998;160:4449-4456.
76. Alexander-Miller MA, Leggatt GR, Berzofsky JA. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci USA 1996;93:4102-4107.
77. Zeh HJ III, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999;162:989-994.
78. Cawthon AG, Lu H, Alexander-Miller MA. Peptide requirement for CTL activation reflects the sensitivity to CD3 engagement: Correlation with CD8cαβ versus CD8αα expression. J Immunol 2001;167:2577-2584.
79. Yee C, et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: Direct evidence of T cell-mediated vitiligo. J Exp Med 2000; 192:1637-1644.
80. Bakker AB, et al. Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope. Int J Cancer 1997;70:302-309.
81. Mendiratta SK, et al. Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2. Cancer Res 2001;61:859-863.
82. Ogg GS, Dunbar RP, Romero P, Chen JL, Cerundolo V. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 1998;188:1203-1208.
83. Overwijk WW, et al. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4 (+) T lymphocytes. Proc Natl Acad Sci USA 1999;96:2982-2987.
84. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999;190:355-366.
85. Shimizu K, Thomas EK, Giedlin M, Mule JJ. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. Cancer Res 2001;61:2618-2624.